Journal article
Ivacaftor Alters Macrophage and Lymphocyte Infiltration in the Lungs Following Lipopolysaccharide Exposure
KH Harwood, RM McQuade, A Jarnicki, EK Schneider-Futschik
ACS Pharmacology and Translational Science | Published : 2022
Abstract
Background and purpose: Cystic fibrosis (CF) is associated with a myriad of respiratory complications including increased susceptibility to lung infections and inflammation. Progressive inflammatory insults lead to airway damage and remodeling, resulting in compromised lung function. Treatment with ivacaftor significantly improves respiratory function and reduces the incidence of pulmonary exacerbations; however, its effect on lung inflammation is yet to be fully elucidated. Experimental approach: This study investigates the effects of ivacaftor on lung inflammation in a lipopolysaccharide (LPS) exposure mouse model (C57BL/6). All groups received intratracheal (IT) administration of LPS (10 ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
E.K.S.-F. is supported by the NHMRC (Grant ID: APP1157287) and Cystic Fibrosis Australia.